Evidence map›Paper›PMID 26306443›Full record

ReviewAdvances in experimental medicine and biology2015

Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches.

George Hajishengallis, Tomoki Maekawa, Toshiharu Abe, Evlambia Hajishengallis, John D Lambris

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Advances in experimental medicine and biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03316521 (Safety, Tolerability, Pharmacokinetics), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
28.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03316521 phase1completednot on this mapstarted 2017, after this paper: background citation

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers

TypeinterventionalSponsorAmyndas Pharmaceuticals S.A.Ran2017 to 2017Enrolled50ConditionsComplement Mediated DiseasesArmsAMY-101
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Periodontal Disease and Age-Related Maculopathy: A Case Report.Clinical medicine insights. Case reports · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Microbiota in health and diseases.Signal transduction and targeted therapy · 2022
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

George HajishengallisDepartment of Microbiology, Penn Dental Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA, geoh@upenn.edu.
Tomoki Maekawa
Toshiharu Abe
Evlambia Hajishengallis
John D Lambris
University of Pennsylvania · US

Funding

Role of complement in kidney disorders: from hemodialysis to transportationP01AI068730 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 2007 to 2018
$16.0M
P. gingivalis as a keystone pathogenR01DE015254 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI HAJISHENGALLIS, GEORGIOS · 2004 to 2018
$4.6M
STRUCTURE-FUNCTION ANALYSIS OF DIFFERENT C3 SPECIESR01AI030040 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 1993 to 2016
$4.1M
Oral Immunity and Adjuvant ReceptorsR01DE017138 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI HAJISHENGALLIS, GEORGIOS · 2006 to 2014
$3.8M
Complement inhibition as sepsis therapyR01GM097747 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LAMBRIS, JOHN D, LUPU, FLOREA · 2011 to 2014
$2.1M
Del-1: Molecular and Cellular Targets in PeriodontitisR01DE024716 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI HAJISHENGALLIS, GEORGIOS · 2015 to 2019
$2.0M
Novel mechanisms and 'complement-ary' therapy in periodontitisR01DE021685 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI HAJISHENGALLIS, GEORGIOS · 2012 to 2016
$2.0M
Complement in AMD: Mechanisms and Therapeutic InterventionR01EY020633 · NEI · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 2011 to 2013
$1.8M
NEI NIH HHS EY020633NEI NIH HHS R01 EY020633NIAID NIH HHS AI030040NIAID NIH HHS AI068730NIAID NIH HHS P01 AI068730NIAID NIH HHS R01 AI030040NIDCR NIH HHS DE015254NIDCR NIH HHS DE017138NIDCR NIH HHS DE021685NIDCR NIH HHS DE024716NIDCR NIH HHS R01 DE015254NIDCR NIH HHS R01 DE017138NIDCR NIH HHS R01 DE021685NIDCR NIH HHS R01 DE024716NIGMS NIH HHS GM097747NIGMS NIH HHS R01 GM097747
6 · The paper itself

Abstract

The complement system is a network of interacting fluid-phase and cell surface-associated molecules that trigger, amplify, and regulate immune and inflammatory signaling pathways. Dysregulation of this finely balanced network can destabilize host-microbe homeostasis and cause inflammatory tissue damage. Evidence from clinical and animal model-based studies suggests that complement is implicated in the pathogenesis of periodontitis, a polymicrobial community-induced chronic inflammatory disease that destroys the tooth-supporting tissues. This review discusses molecular mechanisms of complement involvement in the dysbiotic transformation of the periodontal microbiome and the resulting destructive inflammation, culminating in loss of periodontal bone support. These mechanistic studies have additionally identified potential therapeutic targets. In this regard, interventional studies in preclinical models have provided proof-of-concept for using complement inhibitors for the treatment of human periodontitis.

Indexed as

AnimalsBacteroidaceae InfectionsComplement ActivationComplement Inactivating AgentsComplement System ProteinsDisease Models, AnimalDysbiosisHost-Pathogen InteractionsHumansMacaca fascicularisMicePeptides, CyclicPeriodontitisPorphyromonas gingivalisPyridonesReceptors, Complement1-(ethan-1-ol)-2-methyl-3-hydroxypyridin-4-oneAcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg)Complement Inactivating AgentsComplement System ProteinsPeptides, CyclicPyridonesReceptors, Complement

Identifiers

PMID26306443
PMCPMC4562417
OpenAlexW2238429315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.